In-Vitro Maturation of Oocytes From Polycystic Ovarian Patients Undergoing IVF (IVM)
Retrieval of immature oocytes from women with polycystic ovaries, their in-vitro maturation, fertilization and embryo transfer can prevent hormonal treatment that can lead to ovarian hyperstimulation. In addition, it can decrease discomfort and side-effects of routine daily administration of hormones and it can be cost-effective. Thirty healthy women with Polycystic Ovarian Syndrome aged 20-35, with BMI 18-30 kg/msq will be included in the study. Their immature oocytes will be retrieved from small follicles without any hormonal treatment. The oocytes will be fertilized post in-vitro maturation. The developed embryros will be transferred to the patients as in a routine IVF cycle.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||In-Vitro Maturation of Oocytes From Polycystic Ovarian Patients Undergoing IVF|
- Maturation rate of oocytes, their fertilization rate, cleavage rate and embryo quality. [ Time Frame: one year ]
- Implantation rate and successful delivery. [ Time Frame: one year ]
|Study Start Date:||January 2008|
|Study Completion Date:||January 2009|
Other: In-vitro maturation oocytes
Immature oocytes (development stage GV or M1) will be matured in-vitro in IVM culture medium for approximately 28-32 hours. The oocytes will be routinely observed and when they reach maturation (M2) they will be fertilized. The developed embryo will be transferred to the patient 24 hours post-fertilization.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00561808
|IVF Unit, Hillel Yaffe Medical Center|
|Hadera, Israel, 38100|
|Study Director:||Adrian Ellenbogen, MD||IVF Unit, Hillel Yaffe Medical Center|